-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3036 COVID-19 in Patients with Lymphoma: A Grupo De Estudio Latinoamericano En Linfoproliferativos (GELL) Retrospective Study

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III
Hematology Disease Topics & Pathways:
Coronaviruses, SARS-CoV-2/COVID-19, Diseases, Lymphoma (any), Lymphoid Malignancies
Monday, December 7, 2020, 7:00 AM-3:30 PM

Guilherme Fleury Perini, MD1*, Juan Alejandro Ospina Idarraga2*, Maria Alejandra Torres Viera, MD3*, Brady E Beltran, MD4,5*, Denisse A. Castro, MD6,7, Victoria Otero, MD8*, Mariana Kalmus9*, Lorena Fiad, MD10*, Camila Peña, MD11, Henry Idrobo, MD12,13*, Myrna Candelaria, MD, PharmD14, Alana Von Glasenapp, MD15*, Ivan Perdomo, MD16*, Carolina Feres, MD1*, Maria Prates, MD17, Sally Rose Paredes, MD6,18*, Fernando Pérez-Jacobo, MD19, Ana Ramirez-Ibarguen, MD20*, Claudia Gajardo, MD21*, Macarena Alejandra Roa Salinas22*, Humberto Martínez Cordero, MD23*, Melani Otañez, MD24*, Fabiola Valvert, MD25, Efreen Montaño Figueroa, MD, PhD26*, Marcos Di Stefano, MD27*, Rosio Baena, MD28*, Juan Antonio Choque, MD29*, Virginia Abello, MD30*, Ximena Valladares, MD21*, Sofia Sanchez, MD31*, Cristaldo Nancy, MD32*, Daniela Zambrano33*, Juan Felipe Lasso, MD34*, Andrea Noboa, MD35*, Christine Rojas, MD36*, Larissa LC Teixeira37*, Luis Malpica Castillo, MD38*, Eduardo Sotomayor, MD39, Jorge J. Castillo, MD40 and Luis Villela Villela, MD, MC41*

1Hospital Israelita Albert Einstein, São Paulo, Brazil
2Instituto Nacional de Cancerología, Bogotá, Colombia
3Clinica Santa Sofia, Caracas, Miranda, Venezuela
44Centro de Investigación de Medicina de Precisión, Universidad de San Martin de Porres, Lima, Peru
5Departamento de Oncología y Radioterapia,, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
6Departamento de Oncología y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
7Centro de Investigación de Medicina de Precisión, Universidad de San Martin de Porres, Lima, Peru
8Sección Hematología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
9Clinica Olivos, Buenos Aires, Argentina
10Hematología, Hospital Italiano de La Plata, La Plata, Argentina
11Hematology Department, Hospital Del Salvador, Santiago, Chile
12Hematología Oncología, Grupo Ospedale, Cali, Colombia
13Facultad de Medicina., Universidad Del Valle, Cali, Colombia
14Research Division, Instituto Nacional de Cancerología, Mexico City, Mexico
15Department of Hematology, Instituto de Prevision Social, Asuncion, Paraguay
16Clínica Los Nogales, Bogota, Colombia
17Hematology, Hospital Italiano La Plata, La Plata, Argentina
18Centro de Investigacion de Medicina de Precision, Universidad de San Martin de Porres, Lima, Peru
19Hematology Department, Hospital Central Norte Petróleos Mexicanos, Ciudad DE Mexico, Cdmx, Mexico
20Instituto Nacional de Cancerologia, Mexico, Mexico
21Hospital del Salvador, Santiago, Chile
22Hematología, Hospital Del Salvador, Santiago, Chile
23Instituto Nacional de Cancerologia, Bogota, Bogota, Colombia
24Hematology, Hospital General del Estado, Hermosillo, SO, Mexico
25Instituto De Cancerología y Hospital Dr. Bernardo Del Valle (INCAN), Ciudad de Guatemala, Guatemala
26Hospital General de México, SSA, mexico, EM, Mexico
27Hospital de Clínicas Caracas, Caracas, Venezuela (Bolivarian Republic of)
28Instituto Oncológico Nacional Caja Petrolera de Salud, Cochabamba, Bolivia
29Servicio de Hematologia, Caja Nacional de Salud - Hospital de Especialidades Materno Infantil La Paz, La Paz, La Paz, Bolivia
30Hospital de San José. Fundación Universitaria de Ciencias de la Salud (FUCS), Bogota D.C, Colombia, Colombia
31Hospital La Raza IMSS, Mexico City, Mexico
32Hospital Italiano de Buenos Aires (HIBA), Buenos Aires, Argentina
33Hospital Del Salvador, Santiago, Chile
34Fundación Universitaria San Martín, Cali, Colombia
35Servicio de Hematologia, Instituto Oncológico Nacional Dr. Juan Tanca Marengo, Guayaquil, Ecuador
36Hospital Gustavo Frieke, Viña del Mar, Chile
37Hospital Israelita Albert Einstein, Sao Paulo, Brazil
38The University of Texas MD Anderson Cancer Center, Houston, TX
39George Washington University Cancer Center, Washington, DC
40Bing Center for Waldenström Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA
41Campus Hermosillo, Universidad del Valle de Mexico, Hermosillo, Mexico

Introduction: SARS-COV-2 pandemic has infected approximately 20 million people worldwide and more than 700.000 fatalities have been reported. Patients with malignant hematological diseases are at particular risk for unfavorable outcomes, including intensive care unit (ICU) admission, need for mechanical ventilation (MV) and death. There is paucity of data of the outcome of cancer patients with COVID-19 in low- and middle-income countries. GELL is a collaborative network of hematological centers in 13 countries in Latin America. In this retrospective study, we aimed to look at the outcome of lymphoma patients diagnosed with COVID-19 in Latin America.

Methods: This is a retrospective study including patients with a diagnosis of lymphoma and COVID-19 infection. Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma were excluded from the analysis. COVID-19 diagnosis was done by RT-PCR in all but 3 patients, in whom the diagnosis was done by serology. Active disease was defined as patients with detected disease in any setting (prior to therapy, relapse) or patients currently on treatment. Survival curves were plotted using Kaplan Meier method.

Results: A total of 117 patients were available for analysis. Median age was 60 years old, and 44% of patients had at least one comorbidity, including 32% with hypertension, 17% with obesity, 11% with cardiovascular disease and 17% with diabetes. Most patients had aggressive lymphomas (67%), including 46% of patients with diffuse large B-Cell lymphoma (DLBCL). Follicular lymphomas was observed in 13% of patients and Hodgkin’s lymphoma in 10% of patients. 84% of patients had active disease, and 70% of patients were currently on treatment. With a median follow up of 17 days from COVID-19 diagnosis, 78% were admitted to Hospital, 30% needed ICU support, and 27% needed MV. Importantly, 26% of patients died, most of them within 20 days from diagnosis (Fig. 1). There was no relation between active disease (p=0.23), current treatment (p=0.65) or use of monoclonal antibodies (p=0.24) with death. COVID-19 treatment data was available in 107 patients, and 72 of them received any treatment, being steroids, the most common treatment used (n=59).

Conclusion: We confirm the dismal prognosis of patients with hematological malignancies and COVID-19 infection. In our cohort of Latin America patients with lymphoma and COVID-19, 26% of patients died with a median follow up of 17 days. No impact of current treatment or use of monoclonal antibodies were observed.

Disclosures: Peña: Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sandoz: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Amgen: Speakers Bureau; BindingSite: Research Funding. Idrobo: Amgen: Honoraria, Speakers Bureau; Abbvie: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Tecnofarma: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau. Abello: Novartis: Consultancy, Honoraria; Amgen: Consultancy, Research Funding; Takeda: Honoraria, Research Funding; Dr. Reddy's: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding. Rojas: Novartis: Consultancy; Abbvie: Honoraria; Sandoz: Honoraria; Roche: Honoraria. Castillo: Abbvie: Research Funding; Kymera: Consultancy; Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Beigene: Consultancy, Research Funding; TG Therapeutics: Research Funding. Villela: amgen: Speakers Bureau; Roche: Other: advisory board, Speakers Bureau.

*signifies non-member of ASH